CL2009001870A1 - Composicion farmaceutica que comprende: a) un agente activo de prostaglandina que es 13,14-dihidro-15-ceto-20-etil-pgf2alfa isopropil ester, b) un primer tensoactivo no ionico, c) un segundo tensoactivo no ionico, d) un vehiculo oftalmicamente aceptable, util en el tratamiento de la hipertension ocular (divisional de la solicitud 557-98). - Google Patents

Composicion farmaceutica que comprende: a) un agente activo de prostaglandina que es 13,14-dihidro-15-ceto-20-etil-pgf2alfa isopropil ester, b) un primer tensoactivo no ionico, c) un segundo tensoactivo no ionico, d) un vehiculo oftalmicamente aceptable, util en el tratamiento de la hipertension ocular (divisional de la solicitud 557-98).

Info

Publication number
CL2009001870A1
CL2009001870A1 CL2009001870A CL2009001870A CL2009001870A1 CL 2009001870 A1 CL2009001870 A1 CL 2009001870A1 CL 2009001870 A CL2009001870 A CL 2009001870A CL 2009001870 A CL2009001870 A CL 2009001870A CL 2009001870 A1 CL2009001870 A1 CL 2009001870A1
Authority
CL
Chile
Prior art keywords
ionic surfactant
useful
pharmaceutical composition
pgf2alpha
keto
Prior art date
Application number
CL2009001870A
Other languages
English (en)
Spanish (es)
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001870(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2009001870A1 publication Critical patent/CL2009001870A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
CL2009001870A 1997-03-17 2009-09-16 Composicion farmaceutica que comprende: a) un agente activo de prostaglandina que es 13,14-dihidro-15-ceto-20-etil-pgf2alfa isopropil ester, b) un primer tensoactivo no ionico, c) un segundo tensoactivo no ionico, d) un vehiculo oftalmicamente aceptable, util en el tratamiento de la hipertension ocular (divisional de la solicitud 557-98). CL2009001870A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17

Publications (1)

Publication Number Publication Date
CL2009001870A1 true CL2009001870A1 (es) 2010-01-22

Family

ID=38729083

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001870A CL2009001870A1 (es) 1997-03-17 2009-09-16 Composicion farmaceutica que comprende: a) un agente activo de prostaglandina que es 13,14-dihidro-15-ceto-20-etil-pgf2alfa isopropil ester, b) un primer tensoactivo no ionico, c) un segundo tensoactivo no ionico, d) un vehiculo oftalmicamente aceptable, util en el tratamiento de la hipertension ocular (divisional de la solicitud 557-98).

Country Status (32)

Country Link
EP (1) EP0969846B2 (enExample)
JP (2) JP4920124B2 (enExample)
KR (1) KR100555818B1 (enExample)
CN (1) CN1236775C (enExample)
AR (2) AR002194A1 (enExample)
AT (1) ATE257385T1 (enExample)
AU (1) AU738781B2 (enExample)
BR (2) BRPI9816218B1 (enExample)
CA (1) CA2280089C (enExample)
CL (1) CL2009001870A1 (enExample)
CO (1) CO4940427A1 (enExample)
CY (1) CY2526B1 (enExample)
CZ (1) CZ299833B6 (enExample)
DE (1) DE69820997T3 (enExample)
DK (1) DK0969846T4 (enExample)
EE (1) EE04091B1 (enExample)
ES (1) ES2214706T5 (enExample)
HU (1) HU228896B1 (enExample)
ID (1) ID22389A (enExample)
IL (1) IL131041A0 (enExample)
MY (1) MY122237A (enExample)
NO (1) NO327713B1 (enExample)
NZ (1) NZ337322A (enExample)
PE (1) PE61899A1 (enExample)
PL (1) PL197509B1 (enExample)
PT (1) PT969846E (enExample)
RU (1) RU2197970C2 (enExample)
SI (1) SI0969846T2 (enExample)
TW (1) TW527187B (enExample)
UA (1) UA63938C2 (enExample)
WO (1) WO1998041208A1 (enExample)
ZA (1) ZA982188B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) * 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
DK1321144T3 (da) * 2000-09-13 2011-03-07 Santen Pharmaceutical Co Ltd Øjendråber
WO2002045748A1 (en) * 2000-12-05 2002-06-13 Sankyo Company, Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
ES2331890T3 (es) * 2004-03-18 2010-01-19 R-Tech Ueno, Ltd. Composicion acuosa que comprende un derivado de tiazol.
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
EP1916002B1 (en) * 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
JP5275214B2 (ja) * 2006-03-17 2013-08-28 ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド 酸化に不安定な成分を含む眼科用安定組成物
AU2007313684A1 (en) * 2006-10-31 2008-05-08 Alcon Research, Ltd. PAI-1 binding modulators for the treatment of ocular disorders
JPWO2008096804A1 (ja) * 2007-02-07 2010-05-27 テイカ製薬株式会社 ラタノプロスト含有点眼剤
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
CN101820917B (zh) * 2007-10-08 2013-01-02 佛维雅制药股份有限公司 水性眼科配制剂
AU2009225931B9 (en) * 2008-03-17 2014-04-03 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
JP2014510709A (ja) * 2011-04-12 2014-05-01 株式会社アールテック・ウエノ 眼科用水性組成物
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
HUE057140T2 (hu) 2011-12-07 2022-04-28 Allergan Inc Hatásos lipidszállítás humán könny-filmhez sóérzékeny emulziórendszer alkalmazásával
RU2697844C9 (ru) 2014-11-25 2019-10-01 Аллерган, Инк. Стабилизированные композиции для офтальмологического применения, содержащие омега-3-кислоты
AU2019343188A1 (en) * 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
BR112021020425A2 (pt) 2019-04-12 2021-12-14 Ecolab Usa Inc Composições de limpeza multiuso concentrada e pronta para uso, e, métodos para limpar uma superfície e de fabricação da composição de limpeza multiuso

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458587B1 (en) * 1990-05-22 1993-07-14 R-Tech Ueno Ltd. Synergistic combination for ophthalmic use
IE920397A1 (en) * 1991-02-07 1992-08-12 Allergan Inc 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
JP2742333B2 (ja) * 1994-05-06 1998-04-22 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるビタミンｅトコフェリル誘導体の使用
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
DE69820997T3 (de) 2011-10-06
RU2197970C2 (ru) 2003-02-10
NZ337322A (en) 2001-05-25
BR9808016A (pt) 2000-03-08
PE61899A1 (es) 1999-06-30
SI0969846T1 (en) 2004-06-30
CY2526B1 (en) 2006-02-08
SI0969846T2 (sl) 2010-12-31
EE9900410A (et) 2000-04-17
JP2010043110A (ja) 2010-02-25
ID22389A (id) 1999-10-07
EP0969846B2 (en) 2010-08-25
KR100555818B1 (ko) 2006-03-03
ATE257385T1 (de) 2004-01-15
NO327713B1 (no) 2009-09-14
KR20000076330A (ko) 2000-12-26
CO4940427A1 (es) 2000-07-24
WO1998041208A1 (en) 1998-09-24
DK0969846T4 (da) 2010-12-20
JP4920124B2 (ja) 2012-04-18
PL197509B1 (pl) 2008-04-30
CA2280089C (en) 2009-03-03
HU228896B1 (en) 2013-06-28
HK1026841A1 (en) 2000-12-29
BRPI9816218B1 (pt) 2016-04-12
JP2001515502A (ja) 2001-09-18
DE69820997T2 (de) 2004-12-09
TW527187B (en) 2003-04-11
DE69820997D1 (de) 2004-02-12
HUP0002194A2 (hu) 2000-12-28
ES2214706T5 (es) 2011-02-02
HUP0002194A3 (en) 2012-08-28
EP0969846A1 (en) 2000-01-12
CZ299833B6 (cs) 2008-12-10
AU738781B2 (en) 2001-09-27
ZA982188B (en) 1998-09-17
AU7035398A (en) 1998-10-12
MY122237A (en) 2006-04-29
EP0969846B1 (en) 2004-01-07
NO994481D0 (no) 1999-09-16
AR002194A1 (es) 1998-01-07
CN1249687A (zh) 2000-04-05
IL131041A0 (en) 2001-01-28
ES2214706T3 (es) 2004-09-16
NO994481L (no) 1999-09-16
PL335168A1 (en) 2000-04-10
PT969846E (pt) 2004-05-31
CN1236775C (zh) 2006-01-18
AR011192A1 (es) 2000-08-02
CA2280089A1 (en) 1998-09-24
UA63938C2 (uk) 2004-02-16
DK0969846T3 (da) 2004-04-13
EE04091B1 (et) 2003-08-15
CZ325799A3 (cs) 2000-01-12

Similar Documents

Publication Publication Date Title
CL2009001870A1 (es) Composicion farmaceutica que comprende: a) un agente activo de prostaglandina que es 13,14-dihidro-15-ceto-20-etil-pgf2alfa isopropil ester, b) un primer tensoactivo no ionico, c) un segundo tensoactivo no ionico, d) un vehiculo oftalmicamente aceptable, util en el tratamiento de la hipertension ocular (divisional de la solicitud 557-98).
NO20000467D0 (no) Selvemulgerende formulering for lipofile forbindelser
FI956204A0 (fi) Stabiilit paikalliset retinoidikoostumukset
AR015715A1 (es) Una composicion acondicionadora del cabello
DK1011637T3 (da) Modulation af fyldning af lægemiddel i multivesikulære liposomer
NZ510991A (en) Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders
MY124104A (en) Skin wash composition
CA2332474A1 (fr) Composition de lavage des matieres keratiniques a base d'ester de sorbitan faiblement ethoxyle
ES2154650T3 (es) Composicion que comprende una formulacion con factor de coagulacion viii, procedimiento para su preparacion y uso de un tensioactivo como estabilizador.
ES2098739T3 (es) Composiciones oftalmicas conteniendo una cyclosporin.
NO304261B1 (no) Preparat omfattende en lipofil forbindelse
DK0722313T3 (da) Viskoelastiske sammensætninger af fluorerede organiske forbindelser
ES2196058T3 (es) Enzimas para aguas recreativas.
ES2171658T3 (es) Composiciones surfactantes.
CA2498233A1 (en) Clear ophthalmic solution comprising latanoprost as active ingredient
SG143019A1 (en) Pharmaceutical compositions for oral and topical administration
CO4960657A1 (es) Composicion farmaceutica
CA2264693A1 (en) Azelastine hydrochloride-containing percutaneous preparation having good percutaneous absorbability and reduced skin irritation
ES2189815T3 (es) Composiciones detergentes poco irritantes.
FR2737135B1 (fr) Gels inverses a phase continue fluoree
KR970061250A (ko) 글리클라자이드-함유 연질캅셀제 내용물의 조성물
KR960033448A (ko) 도코사헥사엔산(dha) 함유 수용액 조성물
ECSP982443A (es) Composiciones y metodos para reducir la hipertension ocular